LeadershipAdvocacy & Gov't AffairsHistoryCareers at Joslin
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Adult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingCommercialization and VenturesHealthcare Professionals
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

News Release

Joslin Diabetes Center Announces Alliance with Johnson & Johnson Innovation to Identify Exercise-Related Drug Targets to Improve Diabetes Management

BOSTON (October 9, 2013) – Joslin Diabetes Center announces a research and development alliance with Johnson & Johnson Innovation and its affiliate Janssen Research & Development, LLC, to identify and advance early-stage, novel therapeutic projects for potential for commercialization and product development. The first joint project selected in the alliance will focus on identifying exercise-related drug targets for developing new diabetes treatments.

“Joslin is uniquely positioned to translate findings in the laboratory into new approaches for treatment of diabetes, and our alliance with Johnson & Johnson Innovation and Janssen Research & Development is an excellent example of how we can move our early discoveries to the clinic with our complementary capabilities,” said Dr. Nandan Padukone, Ph.D., MBA, VP of Commercialization and Ventures at Joslin.  “We will continue to explore other technologies with Johnson & Johnson Innovation and mechanisms such as venture creation to advance them quickly towards drug development.”

The new alliance is based on pioneering studies by Joslin researchers showing that exercise can train multiple tissues in the body that in turn stimulate metabolic improvements in other tissues.  “The concept of tissue-to-tissue communication has been around for a while, but more recently we have realized that “trained” tissues may communicate to beneficially affect other tissues,” said Laurie Goodyear, Ph.D., Co-Head of the Integrative Physiology and Metabolism Section at Joslin and senior investigator on this research presented earlier this year at the American Diabetes Association’s 73rd annual Scientific Sessions.  “Our efforts now are to derive specific factors that help this effect and explore the development into potential therapies for diabetes.”

###